ProCE Banner Activity

Phase II Study of Dostarlimab in Locally Advanced, Mismatch Repair–Deficient Rectal Cancer

Slideset Download
Early data showed that among 14 patients with locally advanced, dMMR rectal cancer who completed treatment with the PD-1 inhibitor dostarlimab, all 14 achieved a clinical complete response, without the need for chemoradiotherapy or surgery.

Released: June 14, 2022

Expiration: June 13, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab